Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11225425 | 0.77 | GAA (0.43) | GAAL3MBTL1HDAC1HDAC2POLB | |
| SCHEMBL10540459 | 0.76 | GAA (0.42) | GAAL3MBTL1HDAC1HDAC2POLB | |
| SCHEMBL11225104 | 0.76 | GAA (0.42) | GAAL3MBTL1HDAC1HDAC2POLB | |
| SCHEMBL15632414 | 0.75 | GAA (0.46) | GAAL3MBTL1HDAC1HDAC2POLB | |
| SCHEMBL5800176 | 0.73 | GAA (0.44) | GAAL3MBTL1HDAC1HDAC2POLB | |
| SCHEMBL10402214 | 0.72 | GAA (0.40) | GAAL3MBTL1HDAC1HDAC2POLB | |
| SCHEMBL11202737 | 0.72 | GAA (0.37) | GAAL3MBTL1HDAC1HDAC2POLB | |
| SCHEMBL10404631 | 0.71 | GAA (0.39) | GAAL3MBTL1HDAC1HDAC2POLB | |
| SCHEMBL10644092 | 0.71 | HDAC1 (0.37) | GAAL3MBTL1HDAC1HDAC2POLB | |
| SCHEMBL9328091 | 0.71 | GAA (0.45) | GAAL3MBTL1HDAC1HDAC2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630111-B1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS INC (US) | 2021-11-24 | — | — | EP | disclosed |